Two continents. One simple choice.

Although an ocean may divide them, when it comes to choosing the right pharma services company, distance knows no bounds.

As market leaders in an abecedarian of pharmaceutical services, European-based QUINTA-ANALYTICA are proud to have been chosen to provide a plethora of their offerings by US transdermal patch technology specialists, Greene Street Pharmaceuticals, despite being located a ‘mere’ 7000km away.

Being selected over more local service providers, Quinta-Analytica has been contracted as the exclusive API sourcing partner and CRO for BE studies, bioanalytical analyses, and preclinical studies for Greene Street as it strengthens its foothold in bringing transdermal solutions to the mainstream.

By selecting Quinta-Analytica with its world-class network of services, over 20 years of experience and fully certified coverage of the whole pharmaceutical spectrum, it will enable Greene Street to realize its model of offering a combination of discovery, development, and direct manufacture of transdermals both at home and abroad.

Are looking for a world-class pharmaceuticalindustry service provider? Don’t let geography influence you, get in touch with us today!

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.